"Among the patients with matched samples from breast primary and metastatic sites in this study, there was a significant level of discordance in HER2 expression." — Megan Kruse, MD A team from the ...
Of the 491 patients, 21.2% had HER2-low expression, 30% had HER2 overexpression, and 50% had HER2-negative expression. Among the hormone receptor (HR)–positive patients, 34% had HER2-low expression; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results